4′-(Trifluoromethoxy)acetophenone

We are 4′-(Trifluoromethoxy)acetophenone CAS:85013-98-5 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:4'-(Trifluoromethoxy)acetophenone
CAS.NO:85013-98-5
Synonyms:1-[4-(trifluoromethoxy)phenyl]ethanone
Molecular Formula:C9H7F3O2
Molecular Weight:204.14600
 
Physical and Chemical Properties:
Density:1.278
Boiling point:100ºC
Flash point:190°F
Index of Refraction:1.455
 
Specification:
Appearance:Colourless to yellow clear liquid
Assay:≥98.0%
Moisture:≤0.2%
 
Packing:200 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Organic synthesis intermediate

4'-(Trifluoromethoxy)acetophenone


Related News: Higher-risk MDS is a disease with significant unmet need, and we are pleased to be able to support healthcare professionals seeking access to rigosertib, ahead of its commercial launch,” said Mark Corbett, EVP, Inceptua Medicines Access.2-Butynoic acid China’s pharmaceutical CMO market has recently maintained a growth rate of more than 10%. From the perspective of market structure, the average growth rate of clinical production is 9.5%, while the average growth rate of commercial production will reach 18.7%.Trimethoxy[2-(7-oxabicyclo[4.1.0]hept-3-yl)ethyl]silane China’s pharmaceutical CMO market has recently maintained a growth rate of more than 10%. From the perspective of market structure, the average growth rate of clinical production is 9.5%, while the average growth rate of commercial production will reach 18.7%.4- (Difluorometoxi) bencenosulfonamida CAS:874781-09-6 China’s pharmaceutical CMO market has recently maintained a growth rate of more than 10%. From the perspective of market structure, the average growth rate of clinical production is 9.5%, while the average growth rate of commercial production will reach 18.7%.China’s pharmaceutical CMO market has recently maintained a growth rate of more than 10%. From the perspective of market structure, the average growth rate of clinical production is 9.5%, while the average growth rate of commercial production will reach 18.7%.

Related Products
Product Name
5-Fluoro-1H-indole-3-carboxylic acid View Details
1-O-Acetyl-2,3,5-Tri-O-Benzoyl-Beta-D-Ribofuranose View Details
L-Anserine nitrate View Details
2-aminonicotinic acid manufacturer 5-METHYL-1,3-BENZODIOXOLE manufacturer 3,5-Dibromo-4-hydroxybenzaldehyde manufacturer Glycidyl methacrylate manufacturer 2-Bromotriphenylene manufacturer